$BIO News

Bio-Rad (BIO) Q2 2026 Earnings Call Transcript

Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock

Bio Rad Laboratories (BIO) Earnings And Guidance Put Fair Value Back In Focus

RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $390

Citigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $330

Bio-Rad Laboratories, Inc. Q2 2026 Earnings Call Summary

RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $370

Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $330

Bio-Rad Laboratories Inc (BIO) (Q2 2026) Earnings Call Highlights: Digital PCR Surges 20%+ as ...

Bio-Rad Laboratories Q2 Earnings Call Highlights

Bio-Rad (NYSE:BIO) Falls After Q2 Beat as Life Science Sales Weigh

Bio-Rad Laboratories (BIO) Beats Q2 Earnings Estimates

Bio-Rad Reports Second-Quarter 2026 Financial Results

Bio-Rad Starts Restructuring Plan To Enhance Operating Performance; Restructuring Plan Includes Job Cuts, Function Consolidation, And Facility Closures Worldwide; Expects Pre-Tax Charges Of ~$80M - $90M; Restructuring Program Anticipated To Be Completed By End Of FY27

Bio-Rad Laboratories Lowers FY2026 Sales Guidance of $2.506B-$2.596B vs $2.567B Est

Bio-Rad Laboratories Q2 Adj. EPS $2.62 Beats $1.75 Estimate, Sales $651.000M Beat $623.989M Estimate

Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026

Is Elliott’s Sartorius Push Altering The Investment Case For Bio-Rad Laboratories (BIO)?

Elliott Targets Bio-Rad After 70% Stock Collapse

Why Elliott Sees Hidden Billions Inside Bio-Rad Laboratories